Thelin Has Late July User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Encysive's pulmonary arterial hypertension drug Thelin (sitaxsentan) has a user fee date of July 24, the firm said June 15
You may also be interested in...
Encysive Avoids Additional Trials For Thelin NDA
The firm has submitted a complete response to a recent FDA “approvable” letter using existing data for the pulmonary arterial hypertension drug.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.